IMD 1041
Alternative Names: IMD-1041Latest Information Update: 28 Dec 2022
At a glance
- Originator Institute of Medicinal Molecular Design
- Class Anti-inflammatories; Small molecules
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Chronic obstructive pulmonary disease; Diabetes mellitus; Glaucoma; Pulmonary fibrosis
Most Recent Events
- 28 Dec 2022 No development reported - Clinical-Phase-Unknown for Age-related macular degeneration in Japan (PO)
- 28 Dec 2022 No development reported - Clinical-Phase-Unknown for Diabetes mellitus in Japan (PO)
- 28 Dec 2022 No development reported - Clinical-Phase-Unknown for Glaucoma in Japan (PO)